Alpha 2.0
Login Register
» Articles » PMID: 10638490

Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma

Overview
Journal Invest New Drugs
Publisher Springer
Specialty Oncology
Date 2000 Jan 19
PMID 10638490
Citations 9
Authors
R Dreicer
D C Smith
R D Williams
W A See
Affiliations
Soon will be listed here.
Abstract

This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.

Citing Articles

Manipulating Active Structure and Function of Cationic Antimicrobial Peptide CM15 with the Polysulfonated Drug Suramin: A Step Closer to in Vivo Complexity.

Queme-Pena M, Juhasz T, Mihaly J, Szigyarto I, Horvati K, Bosze S Chembiochem. 2019; 20(12):1578-1590.

PMID: 30720915 PMC: 6618317. DOI: 10.1002/cbic.201800801.

A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.

Borges S, Doppler H, Storz P Breast Cancer Res Treat. 2014; 144(1):79-91.

PMID: 24510012 PMC: 3982927. DOI: 10.1007/s10549-014-2857-2.

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L Cancer Chemother Pharmacol. 2012; 70(1):49-56.

PMID: 22729159 PMC: 3466596. DOI: 10.1007/s00280-012-1887-x.

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.

Lam E, Au J, Otterson G, Wientjes M, Chen L, Shen T Cancer Chemother Pharmacol. 2010; 66(6):1019-29.

PMID: 20107799 PMC: 2919610. DOI: 10.1007/s00280-010-1252-x.

Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

George S, Dreicer R, Au J, Shen T, Rini B, Roman S Clin Genitourin Cancer. 2008; 6(2):79-85.

PMID: 18824429 PMC: 2877588. DOI: 10.3816/CGC.2008.n.012.

References
1.
Eisenberger M, Reyno L, Jodrell D, Sinibaldi V, Tkaczuk K, Sridhara R . Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst. 1993; 85(8):611-21. DOI: 10.1093/jnci/85.8.611. View
2.
La Rocca R, Stein C, Danesi R, Cooper M, Uhrich M, Myers C . A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer. 1991; 67(6):1509-13. DOI: 10.1002/1097-0142(19910315)67:6<1509::aid-cncr2820670608>3.0.co;2-f. View
3.
Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View
4.
HAWKING F . Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978; 15:289-322. DOI: 10.1016/s1054-3589(08)60486-x. View
5.
Stein C, LaRocca R, Thomas R, McAtee N, Myers C . Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989; 7(4):499-508. DOI: 10.1200/JCO.1989.7.4.499. View